– USA, TX – bioAffinity Technologies, Inc. (Nasdaq: BIAF/BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today announced the appointment of Dr. Jamie Platt (Ph.D.) to its Board of Directors effective Dec. 1, 2023, bringing two decades of experience of novel diagnostic technologies to global markets.
“Dr. Platt’s impressive track record in transforming research organizations into successful commercial entities, her commitment to operational excellence and innovation, and her extensive experience in expanding product market share in the diagnostics market make her a valuable asset to our team as we move forward with the commercialization of CyPath Lung, our noninvasive test for the early detection of lung cancer,” bioAffinity Technologies President and CEO Maria Zannes said. “We are pleased to welcome Dr. Platt to our Board where we believe her scientific acumen, business leadership and board experience will be influential in driving bioAffinity’s growth and success.”
Dr. Platt replaces Mohsin Meghji who stepped down from the Board of Directors on Dec. 1, 2023, after serving four years.
About Dr. Jamie Platt
Dr. Jamie Platt was instrumental in two M&A exits for diagnostic companies that were completed in 2022, resulting in a combined value of nearly $1 billion. Dr. Platt was COO of Personal Genome Diagnostics which was acquired by LabCorp for $575 million. She also served as COO at Inivata, Inc. where she led operations in support of a next-generation sequencing liquid biopsy laboratory-developed test, which was acquired by Neogenomics. Dr. Platt began her career at Quest Diagnostics where she assumed progressively greater leadership responsibilities before transitioning to VP of Genomic Solutions at Molecular Pathology Laboratory Network, which provides comprehensive services and innovative technologies in laboratory medicine to clients in pathology groups, hospitals, medical laboratories, and physician groups nationwide.
Dr. Platt currently serves as the Managing Director and CEO of Pictor Limited where she is leading a turnaround by restructuring and accelerating product development. Under her leadership, the company raised Series A funding and enhanced the board with expertise from U.S. and international markets. Concurrently, she is President and CEO of BRIDGenomics, LLC, a private consulting and contract commercialization firm she founded in 2015 to provide molecular and genomic-based strategies to clients.
In addition to her role on the board of Pictor Limited, Dr. Platt has served on the boards of Mobility Health, a health diagnostic company focused on precise, rapid infectious disease testing, and DxTerity, a leader in genomic immune-mediated diagnostic technology that develops easy-to-use, fast and affordable genomic tests for disease diagnosis and monitoring. In addition to her board seats, Dr. Platt has held scientific advisory roles for Roche and Genomics England and served on several working groups in the diagnostics, regulatory, and genomic areas.
“I am deeply honored to join the bioAffinity Technologies Board of Directors,” said Dr. Platt. “As a molecular and cellular biologist, I appreciate the science behind the CyPath Lung technology and recognize its potential to transform patients’ lives by detecting lung cancer and other lung diseases early when outcomes are better. I look forward to contributing to the growth and success of bioAffinity Technologies as this talented team continues to innovate and redefine what’s possible in early-stage cancer detection and treatment.”
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, Inc. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio.
SOURCE: https://bioaffinitytech.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
